Nuvilab officially clarifies the tirzepatide dosages available in its portfolio
Nuvilab hereby officially confirms that the only tirzepatide dosages currently available in its portfolio are:
30 mg · 60 mg · 90 mg · 120 mg
These presentations have been strategically defined based on international standardization, safety, traceability, and strict quality control, meeting the needs of physicians and clinics seeking reliability, consistency, and confidence in product management.
Nuvilab does not manufacture, distribute, commercialize, or recognize any tirzepatide dosages other than the four official presentations listed above. Any reference to different dosages, concentrations, or formats does not belong to the Nuvilab product portfolio.
Maintaining a clear and well-defined product line reflects Nuvilab’s commitment to:
• Technical excellence
• Strict process control
• Transparency with partners and healthcare professionals
• International production and distribution standards
Nuvilab remains focused on delivering solutions aligned with global best practices, prioritizing quality, safety, and clear communication with the market.
Official Brand Position
“At Nuvilab, standardization means safety. That is why we exclusively work with the 30 mg, 60 mg, 90 mg, and 120 mg tirzepatide dosages, ensuring control, traceability, and confidence at every stage.”
